SCHEMBL22070677

SCHEMBL22070677

CCOC(=O)[C@@H]1C[C@H]1c1ccc(F)c(CCO)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP4F2 P78329 2/20 0.41
CYP4A11 Q02928 2/20 0.41
ALDH1A1 P00352 3/20 0.37
SLC9A1 P19634 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
CA1 P00915 4/20 0.36
CA2 P00918 4/20 0.36
CA9 Q16790 4/20 0.36
CA12 O43570 3/20 0.36
MAPT P10636 1/20 0.36
PKM P14618 1/20 0.36
PDE4A P27815 1/20 0.36
PDE4B Q07343 1/20 0.36
PDE4C Q08493 1/20 0.36
PDE4D Q08499 1/20 0.36
CXCR2 P25025 1/20 0.36
RORC P51449 1/20 0.36
SLC5A1 P13866 1/20 0.36
SLC5A2 P31639 1/20 0.36
MAPK1 P28482 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22070968 1.00 CYP4F2 (0.41) CYP4F2CYP4A11ALDH1A1SLC9A1TDP1
SCHEMBL22070676 1.00 CYP4F2 (0.41) CYP4F2CYP4A11ALDH1A1SLC9A1TDP1
SCHEMBL20730314 0.90 ALDH1A1 (0.41) CYP4F2CYP4A11ALDH1A1TDP1CA1
SCHEMBL18272435 0.84 ALDH1A1 (0.47) ALDH1A1SLC9A1CA1CA2CA9
SCHEMBL18272434 0.84 ALDH1A1 (0.47) ALDH1A1SLC9A1CA1CA2CA9
SCHEMBL30782701 0.84 ALDH1A1 (0.47) ALDH1A1SLC9A1CA1CA2CA9
SCHEMBL18272393 0.84 ALDH1A1 (0.47) ALDH1A1SLC9A1CA1CA2CA9
SCHEMBL18272445 0.84 ALDH1A1 (0.47) ALDH1A1SLC9A1CA1CA2CA9
SCHEMBL18272436 0.84 ALDH1A1 (0.47) ALDH1A1SLC9A1CA1CA2CA9
SCHEMBL28404770 0.84 ALDH1A1 (0.47) ALDH1A1SLC9A1CA1CA2CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11365192-B2 Pyridine compound substituted with azole TAISHO PHARMACEUTICAL CO., LTD. (JP) 2022-06-21 US disclosed
US-20210122741-A1 PYRIDINE COMPOUND SUBSTITUTED WITH AZOLE TAISHO PHARMACEUTICAL CO., LTD (JP) 2021-04-29 US disclosed
EP-3666766-A1 PYRIDINE COMPOUND SUBSTITUTED WITH AZOLE Taisho Pharmaceutical Co., Ltd. (JP) 2020-06-17 EP disclosed
CN-110914254-A Azole-substituted pyridine compound 大正制药株式会社 2020-03-24 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210122741-A1 PYRIDINE COMPOUND SUBSTITUTED WITH AZOLE CYP2C19, CYP4A11, CYP11B1 CYP4F2 20/4885CYP4A11 2/4885ALDH1A1 378/4885
US-11365192-B2 Pyridine compound substituted with azole CYP2C19, CYP4A11, CYP11B1 CYP4F2 20/4885CYP4A11 2/4885ALDH1A1 378/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.